Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · GLP-1 Metabolic

Retatrutide vs Tirzepatide

Retatrutide and Tirzepatide are the two most-discussed next-generation incretin agonists. Tirzepatide is a dual GIP/GLP-1 agonist with FDA approval and the strongest head-to-head data against Semaglutide. Retatrutide adds a glucagon-receptor arm and has shown greater Phase 2 weight-loss signals, but remains research-phase.

Bangkok research desk ·

Side-by-side

Retatrutide Tirzepatide
MechanismTriple agonist: GLP-1, GIP, glucagon.Dual agonist: GIP, GLP-1.
Half-lifeExtended (weekly dosing).~5 days.
Dose0.5-12 mg weekly SC.2.5-15 mg weekly SC.
CyclePhase 2 protocol; less standardised.20-week SURMOUNT titration.
Research contextPhase 2 obesity trial: dose-dependent weight loss to ~24% at 48 weeks1.SURMOUNT-1: ~22.5% at 72 weeks with 15 mg2; FDA-approved.
Cost tierHigh.High.

Retatrutide and Tirzepatide compete on both mechanism and magnitude. The mechanistic step is adding the glucagon agonism to what Tirzepatide already provides (GIP + GLP-1). The magnitude step is what the Phase 2 Retatrutide trial reported: dose-dependent mean weight loss approaching 24% of body weight at 48 weeks in the 12 mg arm1. Tirzepatide's SURMOUNT-1 result at 15 mg over 72 weeks was ~22.5%2.

The cross-trial comparison is imperfect because durations differ (48 vs 72 weeks), populations differ slightly, and the titration schedules differ. Head-to-head has not run. But the emerging consensus is that the glucagon component adds energy expenditure that GIP and GLP-1 do not, and that Retatrutide's Phase 3 data (in progress) is likely to confirm a real magnitude advantage if the GI-tolerability profile at 12 mg remains acceptable.

Research-protocol selection turns on risk tolerance and access. Tirzepatide has completed Phase 3 and FDA registration. Retatrutide is Phase 2; its long-term safety, cardiovascular outcomes, and rare-event profile are not characterised. Researchers running hypothesis-generating protocols on the triple-agonist mechanism choose Retatrutide. Researchers running applied protocols with clinical-grade comparators choose Tirzepatide. See GLP-1 research overview for the full class map.

Frequently asked

Has Retatrutide passed Phase 3?
As of the published Phase 2 data, Retatrutide is still in Phase 3 development. Results from confirmatory trials were not published at the time of writing.
Which has greater cardiovascular data?
Neither has completed dedicated cardiovascular-outcomes trials comparable to the SELECT trial for Semaglutide. Tirzepatide's SURPASS programme included cardiovascular-safety monitoring but not a primary CVOT endpoint in SURMOUNT trials.
Do they have different side-effect profiles?
Both share the GLP-1-class GI-tolerability profile (nausea, diarrhoea, constipation). Retatrutide's Phase 2 data did not flag distinct issues at tolerated doses, but long-term surveillance is incomplete.
Research desk
Ordering both Retatrutide and Tirzepatide for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024

All references verified against PubMed via NCBI E-utilities.